Genmab — Januar 2015
-
citat MedWatch: "Der har tidligere været spekuleret i, at Genmab kunne være en opkøbskandidat for de helt store farmaselskaber, men det bliver vurderet som værende tvivlsomt. Årsagen er, at Janssen ejer mere end 10 pct., og det vil gøre det meget vanskeligt, de facto kræve en enormt høj pris, før det kan lade sig gøre.
Årsagen er, at man ikke kan købe Genmab, med mindre man får overbevist Janssen. Derfor er det da heller ikke sandsynligt, at Genmab bliver solgt – -
AKA har et godt skriv på inrater.com
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind